Compare Global X Copper Miners ETF (COPX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Novo Nordisk A/S — how do they compare? Global X Copper Miners ETF trades at $89.3, while Novo Nordisk A/S trades at $45.84 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Global X Copper Miners ETF pays none, and Global X Copper Miners ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| COPX | NVO | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $63.98 |
52-Week Low | $46.08 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX, the Global X Copper Miners ETF, trades at $88.03, up 2.25% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides exposure to copper mining equities, which are leveraged to copper demand from AI data centers and electrification trends. Recent news highlights institutional accumulation and a buying opportunity after a pullback from 2026 highs.
The outlook is positive due to structural copper demand growth, though mining equities have underperformed copper futures year-to-date. Risks include commodity price volatility and supply bottlenecks. Analyst sentiment is bullish, emphasizing COPX as a pick-and-shovel play on AI infrastructure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
